Table 3 Key characteristics

Date

2011–2019

2015–2017

2021–2022

2016–2022

Symptom onset to inclusion (hours)

0–6

0–8

0–12

6–24

Number screened

424

288

507

Data not available

Number of participants

300

131

340

217

Crossover (percentage)

3/154 (1.9) to BMT

7/146 (4.7) to MT

3/66 (4.5) to BMT

14/65 (21.5) to MT

3/226 (1.3) to BMT

3/114 (2.6) to MT

1/110 (0.9) to BMT

4/107 (3.7) to MT

Median NIHSS at presentation (IQR)

Intervention:

21.9

Control:

22.1 (IQR not available)

Intervention:

32 (18–38)

Control:

26 (13–37)

Intervention:

24 (15–35)

Control:

24 (14–35)

Intervention:

20 (14.5–29)

Control:

19 (12–30)

Intravenous thrombolysis (%)

Intervention:

121/154 (78.6)

Control:

116/146 (79.5)

Intervention:

18/66 (27)

Control:

21/65 (32)

Intervention:

69/226 (30.5)

Control:

39/114 (34.2)

Intervention:

15/110 (13.6)

Control:

23/107 (21.5)

Blinding

Open-label, blinded outcome assessment

Open-label, blinded outcome assessment

Open-label, blinded outcome assessment

Open-label, blinded outcome assessment

mRS (≤3)

(percentage)

Intervention:

68/154 (44.1)

Control:

55/146 (37.6)

Intervention:

28/66 (42.4)

Control:

21/65 (32.3)

Intervention:

104/226 (46)

Control:

26/114 (22.8)

Intervention:

51/110 (46.3)

Control:

26/107 (24.2)

Mortality at day 90 (percentage)

Intervention:

59 (38.3)

Control:

63 (43.2)

Intervention:

22 (33.3)

Control:

25 (38.4)

Intervention:

83 (36.7)

Control:

63 (55.2)

Intervention:

34 (30.9)

Control:

45 (42.1)

sICH

(percentage)

Intervention:

6 (4.5)

Control:

1 (0.7)

Intervention:

5 (8)

Control:

0

Intervention:

12 (5)

Control:

0

Intervention:

6 (8.8)

Control:

1 (2.3)

Follow up:

24 hrs, 90 days

24 hrs, 90 days

24 hrs, 90 days

24 hrs, 90 days, 6 months, 1 year